I completed a two-year Research Fellowship on the impact of biological markers on predicting response to pre-operative chemotherapy in breast cancer at Cancer Research UK’s Gray Laboratory (2001-2003).
My data was presented at international oncology meetings and published in a number of medical journals.
I firmly believe clinical research is crucial to evaluate new therapies and improve existing treatments.
I actively participate in the Kent Oncology Centre trial programme and offer patients entry into clinical trials in Kent, or by referral to The Royal Marsden and other tertiary London hospitals, where possible.
I review my practice regularly and contribute to national audits to ensure I am compliant with national and NICE guidelines.
I participate in regional lung cancer audits which are regularly presented at a national oncology meeting.
Subcutaneous Trastuzumab (Herceptin®):
A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer
Prediction of response to neoadjuvant systemic therapy for operable primary breast cancer
University of London 2009